Paclitaxel is an antineoplastic agent widely used to treat several solid tumor types. The
primary mechanism of action of paclitaxel is based on microtubule stabilization inducing cell …

The anti-tumor properties of Toll-like receptor (TLR) 9 agonist CpG oligodeoxynucleotides
(ODN) are enhanced by combinations with several cytotoxic chemotherapy regimens. The …

Paclitaxel (PTX) is an important cancer chemotherapeutic agent that binds to β-tubulin and
prevents mitosis through microtubule overstabilization. Recent evidence also implicates PTX …

Overexpression of Toll-like receptor-4 (TLR4) in human tumors often correlates with
chemoresistance and metastasis. We found that TLR4 is overexpressed in the majority of …

Emerging evidence shows that the efficacy of chemotherapeutic drugs is reliant on their
capability to induce immunogenic cell death (ICD), thus transforming dying tumor cells into …

The antitumor effects of paclitaxel are generally attributed to the suppression of microtubule
dynamics resulting in defects in cell division. New data demonstrated that in ultralow …

Background Paclitaxel has been reported to be a ligand to Toll like receptor 4 (TLR4).
Myeloid differentiation factor 88 (MyD88) was described as a myeloid differentiation primary …

Evidence suggests that an inflammatory profile of cytokines and chemokines persisting at a
particular site would lead to the development of a chronic disease. Recent studies implicate …

Current therapy of gynecologic malignancies consists of platinum-containing chemotherapy.
Resistance to therapy is associated with increased levels of interleukin (IL)-6 and …

Myeloid cells play a key role in the outcome of anti-tumor immunity and response to anti-
cancer therapy, since in the tumor microenvironment they may exert both stimulatory and …